All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Despite the ups and downs of the general markets and a U.S. government shutdown at the beginning of the year that contributed to no biopharma companies graduating to the public ranks in January, the enthusiasm for biopharma IPOs has remained steady since then. In fact, a flurry of IPO listings on U.S. stock exchanges last month helped bring the total of those offerings to 30 at the halfway point in the year.